A number of research firms have changed their ratings and price targets for Prothena (NASDAQ: PRTA):
- 5/14/2026 – Prothena was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 5/8/2026 – Prothena had its “outperform” rating reaffirmed by Citigroup Inc..
- 5/8/2026 – Prothena had its price target raised by Citizens Jmp from $19.00 to $20.00. They now have a “market outperform” rating on the stock.
- 4/27/2026 – Prothena was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.
Featured Stories
- Five stocks we like better than Prothena
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Prothena Corporation plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation plc and related companies with MarketBeat.com's FREE daily email newsletter.
